Ashwagandha: Clinical Dose Ranges and What the Research Describes

What ashwagandha is

Ashwagandha (Withania somnifera) is a medicinal plant used in Ayurvedic tradition for centuries. It is classified as an adaptogen — a substance studied for its potential to modulate physiological responses to stress. The root is the part most commonly used in supplement preparations.

Two standardised extract forms appear most frequently in clinical trials: KSM-66, standardised to at least 5% withanolides from root only, and Sensoril, standardised to at least 10% withanolides from root and leaf. Unstandardised ashwagandha root powder is also widely sold but has far less trial data behind it.

The clinical dose range

Lower doses of 125–250 mg/day appear in some trials, with mixed results. Trials using unstandardised root powder have used higher gram-level doses (1,000–5,000 mg/day) with less consistent outcomes, likely reflecting lower withanolide concentrations.

What trials have measured

The strongest trial evidence for ashwagandha relates to self-reported stress and cortisol levels. Multiple randomised controlled trials in stressed but otherwise healthy adults have found reductions in perceived stress scores and serum cortisol at 60 days at 300–600 mg/day of standardised extract. Effect sizes are modest and the trials are generally small (60–120 participants).

Sleep quality has been examined in several trials. Outcomes measured include sleep onset latency, total sleep time, and subjective sleep quality. Results have generally favoured ashwagandha over placebo, but trials rely predominantly on self-report instruments rather than polysomnography.

Physical performance — specifically muscular strength and recovery — has been studied in resistance-trained men. Trials report modest increases in bench press and leg press strength over 8 weeks at 600 mg/day compared to placebo. The mechanistic explanation typically offered relates to reduced exercise-induced cortisol, but causality has not been established.

Testosterone has been measured in some trials; small increases in men with reproductive health concerns have been reported. The evidence in healthy men with normal testosterone is weaker and less consistent.

Underdosing in commercial products

Underdosing is common in multi-ingredient adaptogen and stress-support blends. The most frequent patterns are:

• Proprietary blends: Ashwagandha listed inside a named blend alongside five or more other herbs, making the individual dose unverifiable.
• Low-standardisation powder: Products using unstandardised root powder at 100–200 mg/serving, which likely delivers far lower withanolide content than the trial doses.
• Form mismatch: Products claiming clinical equivalence to trial data while using a different extract form (e.g. leaf-only extract vs. root extract used in cited trials).

Documented safety considerations

Ashwagandha is generally well tolerated in short-term trials at the studied doses. Reported adverse effects are typically mild and gastrointestinal. Several considerations are documented in the published literature:

• Thyroid interactions: Ashwagandha may influence thyroid hormone levels. Individuals with thyroid conditions or taking thyroid medication should consult a clinician before use.
• Rare hepatotoxicity: A small number of case reports of drug-induced liver injury associated with ashwagandha products have been published. Causality is not established in all cases, and some cases involved multi-ingredient products, but the signal warrants attention.
• Pregnancy: Ashwagandha is not recommended during pregnancy based on traditional contraindication and limited safety data.

How Proco Scanner evaluates it

When the Scanner reads an ashwagandha ingredient, it checks whether the declared dose falls within the 300–600 mg/day range used in positive trials, and whether the extract is standardised. Products using unstandardised powder or undisclosed extract ratios are flagged accordingly.

Proco Scanner reads any supplement label and surfaces what the published research describes for each ingredient — dose, evidence quality, and known considerations. Coming to iOS. Join the waitlist for early access.